Literature DB >> 17570931

Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity.

Arndt Petermann1, Jurgen Floege.   

Abstract

A decrease in podocyte number contributes to the development of glomerulosclerosis in most forms of glomerular disease [1, 2, 3, 4, 5]. Traditionally, it has been argued that this decrease may be caused by the inability of podocytes to proliferate and replace those lost following immune, metabolic, toxic or hemodynamic injury. These data contrast with recent studies showing that podocytes are able to enter the cell cycle after injury, to progress through the different phases of the cell cycle and even enter mitosis. However, experimental and human data suggest that entry of podocytes into the cell cycle may result in reduced adhesion to the glomerular basement membrane with subsequent loss of podocytes into the urine and excretion of both viable and apoptotic podocytes. Viable urinary podocytes can be cultivated ex vivo for up to 2-3 weeks and in experimental models precede the onset of proteinuria. More importantly, podocyturia can decrease despite persistent proteinuria. The latter observation suggests that podocyturia may serve as the first non-invasive marker of 'active' glomerular damage and might thus drive therapeutic interventions in the future. However, at present technical issues still prevent a broad clinical application of podocyturia detection in clinical practice. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570931     DOI: 10.1159/000101799

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  28 in total

1.  Increased urinary podocytes following indomethacin suggests drug-induced glomerular injury.

Authors:  Alison L Kent; Linda Brown; Margaret Broom; Amy Broomfield; Jane E Dahlstrom
Journal:  Pediatr Nephrol       Date:  2012-03-14       Impact factor: 3.714

2.  Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity.

Authors:  Chayanut Suwanpen; Phonethipsavanh Nouanthong; Veeravich Jaruvongvanich; Krit Pongpirul; Wannarat Amornnimit Pongpirul; Asada Leelahavanichkul; Talerngsak Kanjanabuch
Journal:  J Nephrol       Date:  2015-04-24       Impact factor: 3.902

3.  Effects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia.

Authors:  Guixiang Chen; Lihong Zhang; Xiaohong Jin; Yunjiao Zhou; Jianying Niu; Jing Chen; Yong Gu
Journal:  Reprod Sci       Date:  2012-09-18       Impact factor: 3.060

Review 4.  Podocyte biology for the bedside.

Authors:  J Ashley Jefferson; Charles E Alpers; Stuart J Shankland
Journal:  Am J Kidney Dis       Date:  2011-06-29       Impact factor: 8.860

Review 5.  Minimal change nephropathy and focal segmental glomerulosclerosis.

Authors:  Peter W Mathieson
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

6.  Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies.

Authors:  Patrícia Garcia Rodrigues; Rafael Nazário Bringhenti; Jonathan Frapporti do Nascimento; Gabriel Joelsons; Mariane dos Santos; Sane Pereira; Francisco Veríssimo Veronese
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  C3G overexpression in glomerular epithelial cells during anti-GBM-induced glomerulonephritis.

Authors:  Victoriya A Rufanova; Elias Lianos; Anna Alexanian; Elena Sorokina; Mukut Sharma; Ann McGinty; Andrey Sorokin
Journal:  Kidney Int       Date:  2008-09-10       Impact factor: 10.612

8.  SPARC accelerates disease progression in experimental crescentic glomerulonephritis.

Authors:  Amy N Sussman; Tong Sun; Ronald M Krofft; Raghu V Durvasula
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

9.  Urinary exosomal transcription factors, a new class of biomarkers for renal disease.

Authors:  Hua Zhou; Anita Cheruvanky; Xuzhen Hu; Takayuki Matsumoto; Noriyuki Hiramatsu; Monique E Cho; Alexandra Berger; Asada Leelahavanichkul; Kent Doi; Lakhmir S Chawla; Gabor G Illei; Jeffrey B Kopp; James E Balow; Howard A Austin; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2008-05-28       Impact factor: 10.612

10.  ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases.

Authors:  Paul Gutwein; Anja Schramme; Mohamed Sadek Abdel-Bakky; Kai Doberstein; Ingeborg A Hauser; Andreas Ludwig; Peter Altevogt; Stefan Gauer; Anja Hillmann; Thomas Weide; Christine Jespersen; Wolfgang Eberhardt; Josef Pfeilschifter
Journal:  J Biomed Sci       Date:  2010-01-13       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.